42910 Federal Register / Vol. 83, No. 165 / Friday, August 24, 2018 / Notices 

Expert_Consultation_on_Rabies_Postexposure_Prophylaxis.pdf (accessed 

January 9, 2017). 

39. See https://armypubs.army.mil/ 

ProductMaps/PubForm/AR_

Details.aspx?ID=0902c85180010355 

(accessed May 5, 2017). 

40. CDC, ‘‘Cost of Rabies Prevention,’’ 

updated August 3, 2015; available at 

https://www.cdc.gov/rabies/location/ 

usa/cost.html (accessed February 9, 

2017). 

41. Gullo, F.P., S.A. Rossi, J.C. Sardi, et al., 

‘‘Cryptococcosis: Epidemiology, Fungal 

Resistance, and New Alternatives for 

Treatment,’’ European Journal of Clinical 

Microbiology and Infectious Diseases, 

32:1377–1391, 2013. 

42. CDC, ‘‘C. neoformans Infection 

Statistics;’’ available at https://

www.cdc.gov/fungal/diseases/ 

cryptococcosis-neoformans/ 

statistics.html (accessed August 8, 2016). 

43. Makadzange, A.T. and G. McHugh, ‘‘New 

Approaches to the Diagnosis and 

Treatment of Cryptococcal Meningitis,’’ 

Seminars in Neurology, 34(1):47–60, 

2014. 

44. Perfect, J.R., W.E. Dismukes, F. Dromer, 

et al., ‘‘Clinical Practice Guidelines for 

the Management of Cryptococcal 

Disease: 2010 Update by the Infectious 

Disease Society of America,’’ Clinical 

Infectious Diseases, 50:291–322, 2010. 

45. Rothe, C., D.J. Sloan, P. Goodson, et al., 

‘‘A Prospective Longitudinal Study of 

the Clinical Outcomes from Cryptococcal 

Meningitis Following Treatment 

Induction with 800 mg Oral Fluconazole 

in Blantyre, Malawi,’’ PLOS One, 

8(6):e67311, 2013. 

46. Park, B.J., K.A. Wannemuehler, B.J. 

Marston, et al., ‘‘Estimation of the 

Current Global Burden of Cryptococcal 

Meningitis Among Persons Living with 

HIV/AIDS,’’ AIDS, 23:525–530, 2009. 

47. Mirza, S.A., M. Phelan, D. Rimland, et al., 

‘‘The Changing Epidemiology of 

Cryptococcosis: An Update from 

Population-Based Active Surveillance in 

2 Large Metropolitan Areas, 1992–2000,’’ 

Clinical Infectious Diseases, 36(6):789– 

794, 2003. 

48. Pyrgos, V., A.E. Seitz, C.A. Steiner, et al., 

‘‘Epidemiology of Cryptococcal 

Meningitis in the US: 1997–2009,’’ PLOS 

One, 8(2):e56269, 2013. 

49. CDC, ‘‘Emergence of Cryptococcus 

gattii—Pacific Northwest, 2004–2010,’’ 

Morbidity and Mortality Weekly Report, 

59(28):865–868, 2010 available at https:// 

www.cdc.gov/mmwr/preview/ 

mmwrhtml/mm5928a1.htm?s_

cid=mm5928a1_w. 

50. Espinel-Ingroff, A. and S.E. Kidd, 

‘‘Current Trends in the Prevalence of 

Cryptococcus Gattii in the United States 

and Canada,’’ Infection and Drug 

Resistance, 8:89–97, May 11, 2015. 

51. WHO, ‘‘Rapid Advice: Diagnosis, 

Prevention and Management of 

Cryptococcal Disease in HIV-Infected 

Adults, Adolescents and Children,’’ 

December 2011; available at http://

www.who.int/hiv/pub/cryptococcal_

disease2011/ (accessed August 8, 2016). 

52. Joint United Nations Programme on HIV/ 

AIDS (UNAIDS), ‘‘Global Report: 

UNAIDS Report on the Global AIDS 

Epidemic 2013;’’ available at http://

files.unaids.org/en/media/unaids/ 

contentassets/documents/epidemiology/ 

2013/gr2013/UNAIDS_Global_Report_

2013_en.pdf (accessed August 8, 2016). 

Dated: August 21, 2018. 

Leslie Kux, Associate Commissioner for 

Policy. 

[FR Doc. 2018–18314 Filed 8–23–18; 8:45 am] 

BILLING CODE 4164–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Health Resources and Services 

Administration 

Agency Information Collection 

Activities: Submission to OMB for 

Review and Approval; Public Comment 

Request; The Secretary’s Discretionary 

Advisory Committee on Heritable 

Disorders in Newborns and Children’s 

Public Health System Assessment 

Surveys OMB No. 0906–0014—Revised 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services. 

ACTION: Notice. 

SUMMARY: In compliance with of the 

Paperwork Reduction Act of 1995, 

HRSA has submitted an Information 

Collection Request (ICR) to the Office of 

Management and Budget (OMB) for 

review and approval. Comments 

submitted during the first public review 

of this ICR will be provided to OMB. 

OMB will accept further comments from 

the public during the review and 

approval period. 

DATES: Comments on this ICR should be 

received no later than September 24, 

2018. 

ADDRESSES: Submit your comments to 

paperwork@hrsa.gov or mail the HRSA 

Information Collection Clearance 

Officer, Room 14N136B, 5600 Fishers 

Lane, Rockville, MD 20857. 

FOR FURTHER INFORMATION CONTACT: To 

request a copy of the clearance requests 

submitted to OMB for review, email Lisa 

Wright-Solomon, the HRSA Information 

Collection Clearance Officer at 

paperwork@hrsa.gov or call (301) 443– 

1984. 

SUPPLEMENTARY INFORMATION: 

Information Collection Request Title: 

The Secretary’s Discretionary Advisory 

Committee on Heritable Disorders in 

Newborns and Children’s Public Health 

System Assessment Surveys OMB No. 

0906–0014—Revised. 

Abstract: The purpose of the public 

health system assessment surveys is to 

inform the Secretary’s Discretionary 

Advisory Committee on Heritable 

Disorders in Newborns and Children 

(Committee) on the ability to add 

newborn screening for particular 

conditions within a state, including the 

feasibility, readiness and overall 

capacity to screen for a new condition. 

The Committee was established under 

Section 1111 of the Public Health 

Service Act, 42 U.S.C. 300b–10, as 

amended in the Newborn Screening 

Saves Lives Reauthorization Act of 

2014. The Committee is governed by the 

provisions of the Federal Advisory 

Committee Act, as amended (5 U.S.C. 

App.), which sets forth standards for the 

formation and use of advisory 

committees. The purpose of the 

Committee is to provide the Secretary 

with recommendations, advice, and 

technical information regarding the 

most appropriate application of 

technologies, policies, guidelines, and 

standards for: (a) Effectively reducing 

morbidity and mortality in newborns 

and children having, or at risk for, 

heritable disorders; and (b) enhancing 

the ability of state and local health 

agencies to provide for newborn and 

child screening, counseling, and health 

care services for newborns and children 

having, or at risk for, heritable 

disorders. Specifically, the Committee 

makes systematic evidence-based 

recommendations on newborn screening 

for conditions that have the potential to 

change the health outcomes for 

newborns. 

The Committee tasks an external 

workgroup to conduct systematic 

evidence-based reviews for conditions 

being considered for addition to the 

Recommended Uniform Screening 

Panel, and their corresponding newborn 

screening test(s), confirmatory test(s), 

and treatment(s). Reviews also include 

an analysis of the benefits and harms of 

newborn screening for a selected 

condition at a population level and an 

assessment of state public health 

newborn screening programs’ ability to 

implement the screening of a new 

condition. 

Need and Proposed Use of the 

Information: HRSA proposes that the 

data collection surveys be administered 

by the Committee’s external Evidence 

Review Group to all state newborn 

screening programs in the United States 

up to twice a year for two conditions. 

The surveys were developed to capture 

the following: (1) The readiness of state 

public health newborn screening 

programs to expand newborn screening 

to include the target condition; (2) 

specific requirements of screening for 


daltland on DSKBBV9HB2PROD with NOTICES
Federal Register / Vol. 83, No. 165 / Friday, August 24, 2018 / Notices 42911 

the condition that could hinder or 

facilitate its implementation in each 

state; and (3) estimated timeframes 

needed for each state to complete major 

milestones toward full newborn 

screening of the condition. 

HRSA published the 60-day notice on 

June 5, 2018 (FR Doc. 2018–12019). 

There were no comments received 

during the 60-day comment period. The 

survey tools have been revised to 

streamline responses to decrease the 

burden on the respondents, provide 

clarity with regard to what is being 

asked, ensure the survey can 

accommodate different types of 

conditions that may be nominated in the 

future, and offer additional response 

options. To accomplish this, questions 

were deleted, consolidated, reordered, 

and new questions were added to 

address gaps in information identified 

by those who have completed the 

survey and utilized the survey results. 

The data gathered will inform the 

Committee on the following: (1) 

Feasibility of implementing populationbased screening for the target condition; 

(2) readiness of state newborn screening 

programs to adopt screening for the 

condition; (3) identify gaps in feasibility 

or readiness to screen for the condition; 

and (4) identify areas of technical 

assistance and resources needed to 

facilitate screening for conditions with 

low feasibility or readiness. 

Likely Respondents: The respondents 

to the survey will be State and territorial 

newborn screening programs. 

Burden Statement: Burden in this 

context means the time expended by 

persons to generate, maintain, retain, 

disclose or provide the information 

requested. This includes the time 

needed to review instructions; to 

develop, acquire, install and utilize 

technology and systems for the purpose 

of collecting, validating and verifying 

information, processing and 

maintaining information, and disclosing 

and providing information; to train 

personnel and to be able to respond to 

a collection of information; to search 

data sources; to complete and review 

the collection of information; and to 

transmit or otherwise disclose the 

information. The total annual burden 

hours estimated for this ICR are 

summarized in the table below. 

TOTAL ESTIMATED ANNUALIZED BURDEN—HOURS

Form name Number of 

respondents 

Number of 

responses per 

respondent 

Total 

responses 

Average 

burden per 

response 

(in hours) 

Total burden 

hours 

INITIAL Survey of the Secretary’s Discretionary Advisory 

Committee on Heritable Disorders in Newborns and 

Children’s Public Health System Assessment ................. 59 ** 2 118 10.0 1,180 

FOLLOW-UP Survey of the Secretary’s Discretionary Advisory Committee on Heritable Disorders in Newborns 

and Children’s Public Health System Assessment .......... * 30 ** 2 60 2.0 120 

Total .............................................................................. 89 ........................ 178 ........................ 1,300 

* Up to 30 States and/or Territories will be asked to complete a follow-up survey. 

** Up to two conditions may be reviewed per year. Therefore, there will be two initial surveys and two follow-up surveys per year. 

Amy P. McNulty, 

Acting Director, Division of the Executive 

Secretariat. 

[FR Doc. 2018–18292 Filed 8–23–18; 8:45 am] 

BILLING CODE 4165–15–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

Request for Nominations for the 

Advisory Committee on Training in 

Primary Care Medicine and Dentistry 

AGENCY: Health Resources and Services 

Administration (HRSA), Department of 

Health and Human Services (HHS). 

ACTION: Notice of request for 

nominations. 

SUMMARY: HRSA is requesting 

nominations to fill vacancies on the 

Advisory Committee on Training in 

Primary Care Medicine and Dentistry 

(ACTPCMD). The ACTPCMD is 

authorized by Section 749 of the Public 

Health Service (PHS) Act. The Advisory 

Committee is governed by provisions of 

the Federal Advisory Committee Act 

(FACA), as amended, which sets forth 

standards for the formation and use of 

advisory committees, and applies to the 

extent that the provisions of FACA do 

not conflict with the requirements of 

PHS Act Section 749. 

DATES: HRSA will receive nominations 

on a continuous basis. 

ADDRESSES: Written nominations for 

membership can be submitted by mail 

to Advisory Council Operations, Bureau 

of Health Workforce, HRSA, Room 

11W45C, 5600 Fishers Lane, Rockville, 

Maryland 20857 or sent by email to 

BHWAdvisoryCouncilFRN@hrsa.gov. 

FOR FURTHER INFORMATION CONTACT: 

Kennita R. Carter, MD, Designated 

Federal Official, ACTPCMD at 301–945– 

3505 or email kcarter@hrsa.gov. A copy 

of the current committee membership, 

charter, and reports can be obtained by 

accessing the ACTPCMD website 

https://www.hrsa.gov/advisorycommittees/primarycare-dentist/ 

index.html. 

SUPPLEMENTARY INFORMATION: The 

ACTPCMD provides advice and 

recommendations to the Secretary of the 

Department of Health and Human 

Services (Secretary), the Senate 

Committee on Health, Education, Labor 

and Pensions, and the House of 

Representatives Committee on Energy 

and Commerce on matters concerning 

policy, program development, and other 

matters of significance concerning the 

medicine and dentistry activities under 

Section 747 of the PHS Act, as it existed 

upon the enactment of Section 749 of 

the PHS Act in 1998. In addition, the 

ACTPCMD develops, publishes, and 

implements performance measures and 

longitudinal evaluations for programs 

under Part C of Title VII of the PHS Act, 

as well as recommends appropriation 

levels for programs under this part. 

Meetings are held twice a year. 

Specifically, HRSA is requesting 

nominations for voting members of the 

ACTPCMD representing allopathic 

medicine, osteopathic medicine, family 

medicine, general internal medicine, 

general pediatrics, physician assistant, 

general dentistry, pediatric dentistry, 

public health dentistry, dental hygiene, 

advanced practice nurse programs, and 

other health professionals engaged in 

primary care or oral health 

interprofessional training. Among these 

nominations, students, residents, or 

fellows representing allopathic 


daltland on DSKBBV9HB2PROD with NOTICES